COVID-19 Update | March 27, 2020

COVID-19 News

COVID-19 Update | March 27, 2020

March 27, 2020

As circumstances around coronavirus (COVID-19) continue to evolve quickly, the California Biotechnology Foundation wants to keep you informed about the progress being made by biotechnology researchers in California and across the nation to expand available testing, treat the virus and prevent its spread.

The following resources track what progress has been made as of March 27, 2020. Notable advancements include


  • Inovio Pharmaceuticals (San Diego, CA) is in the development phase for a COVID-19 vaccine.
  • Novartis has committed to donating up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response.
  • Takeda is developing a treatment approach that uses concentrated antibodies and may be available in nine to 18 months.


Recent News:


  • Pharmas to share assets in COVID-19 consortium led by Narasimhan, Gates
    BioCentury – March 26, 2020                                                                  Global alliances among public, private and non-profit entities to counter COVID-19 continue to gather steam, with one of the latest alliances comprising over a dozen life sciences companies and the Gates Foundation.
  • These Drugs Are Helping Our Coronavirus Patients
    Wall Street Journal – March 22, 2020
    A flash of potential good news from the front lines of the coronavirus pandemic: A treatment is showing promise. Doctors in France, South Korea and the U.S. are using an antimalarial drug known as hydroxychloroquine with success.


California Biotechnology Foundation will continue to monitor breaking news and provide updates weekly.


Stay informed on the latest news and trends on the economic and health benefits of this important industry by visiting the new


If you have any questions about informational briefings contact California Biotechnology Foundation Executive Director Patty Cooper at (916)764-2434 or [email protected].